Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.75 -0.36 (-0.72%)
Streaming Delayed Price Updated: 12:29 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
37 38 Next >
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.  
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
How Is The Market Feeling About Sanofi?
 
Via Benzinga
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? 
Via Chartmill
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Looking Into Sanofi's Recent Short Interest
 
Via Benzinga
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
The U.S. 
Via Benzinga
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... 
Via Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals. 
Via Chartmill
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
This Stock Just Dropped By 15%: Is It a Buy?
Now could be a great opportunity to buy low. 
Via The Motley Fool
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? 
Via Chartmill
Pfizer and Sanofi shares fall, which one to scoop up?
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows 
Via MarketBeat
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today?
MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million  
Via Benzinga
Sanofi (SNY) Q3 2023 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.